Comparison of the effect of Intravenous immunoglobulin and rhophylac
Not Applicable
- Conditions
- Idiopathic thrombocytopenic purpura.Idiopathic thrombocytopenic purpura (Evans syndrome)
- Registration Number
- IRCT2012102811289N1
- Lead Sponsor
- Arak University of Medical Sciences, Vice Chancellor for Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1.Age upper 1 year and lower 15 years old in patients with acute or chronic ITP
2.Platelets <30000 at the time of treatment
3.Patients entered in the study that parental consent was obtained
Exclusion criteria:
1.Splenectomy patients
2.Hemoglobin below 10 g/dL
3.Patients who have been treated with IVIG or rhophylac in the past three weeks
4.Patients with renal insufficiency
5.Total bilirubin above 2 mg per deciliter and higher than normal liver enzymes
6.Patients who have a positive direct Coombs test
7.Patients who are infected with HIV or hepatitis C or B
8.Patients with lupus erythematosus
9.Patients with cardiovascular disease
10.Rh-negative patients
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Platelet count. Timepoint: Sixth hour and days 3, 7, and 14 after treatment. Method of measurement: complete blood count.;Fever. Timepoint: since 6 hours after infusion. Method of measurement: mercury thermometer.;Hemolysis. Timepoint: 6 hours after infusion. Method of measurement: complete blood count.;Allergic reaction. Timepoint: 6 hours after infusion. Method of measurement: clinical manifestations.
- Secondary Outcome Measures
Name Time Method